ArticleJournal of translational medicine2026
PET imaging utility of a novel Aβ-tracking PET radiotracer, [
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Synthesis, Radiochemistry, and Preclinical Assessment of the First GPR39 PET Imaging Agent.Journal of medicinal chemistry · 2026Article
- Meeting report for the Second International Conference on Unconventional Animal Models of Alzheimer's Disease and Aging (UAMAA 2026).Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundAlzheimer’s disease is characterized by the deposition of amyloid-beta (Aβ) plaques, necessitating early detection and reliable biomarkers for effective intervention. Non-human primates, particularly aged vervet monkeys, offer valuable models for studying age-related Aβ pathology due to their close phylogenetic relationship to humans and similar neuropathological features.
methodsThis study assessed the utility of [18F]FC119S, a novel Aβ-targeting PET radiotracer, in aged vervet monkeys. The radiochemistry of [18F]FC119S was optimized and automated to ensure high radiochemical purity and molar activity. PET/MRI imaging was performed to evaluate tracer uptake, distribution, and washout kinetics. Correlations between [18F]FC119S uptake and cerebrospinal fluid (CSF) and plasma biomarkers—including Aβ42/40 ratio, pTau181, neurofilament light chain (NfL), and pTau181/Aβ42 ratio—were analyzed. Autoradiography was conducted to validate regional tracer binding in brain tissues.
results[18F]FC119S demonstrated high brain uptake, rapid washout, and widespread cortical distribution in vervet monkeys, mirroring patterns observed in human studies. Tracer uptake showed negative associations with CSF Aβ42/40 ratio in Aβ-affected regions, and significant positive correlations with CSF pTau181 and CSF pTau181/Aβ42 ratio in the temporal lobe. Additionally, significant positive correlations were observed between [18F]FC119S uptake and CSF NfL in the anterior cingulate gyrus, parietal, and occipital lobes. Autoradiography confirmed elevated tracer binding in specific brain regions of older vervets with low CSF Aβ42 compared to younger counterparts.
conclusionsThese findings validate [18F]FC119S as a promising PET radiotracer for tracking Aβ deposition in aged vervet monkeys. Its imaging characteristics and biomarker correlations support its translational potential for Alzheimer’s disease research and early diagnostic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.